News

Cerillo Unveils Co-Culture Duet System for Real-Time Observation of Microbial Interaction Studies

Cerillo, a biotechnology company at the forefront of developing advanced research platforms for the study of the microbiome, hosted demonstrations of the company’s new co-culture duet system at ASM Microbe 2023.

Cerillo’s co-culture system will enable researchers to observe and study individual microbial populations in real time and measure the growth of one microbial population alongside other populations. The system’s porous barrier can physically isolate populations while maintaining fluidic contact, allowing researchers to mimic natural microbiome conditions and study the interactions between microorganisms.

The co-culture system is also scalable since it can be read in multiple microplate readers, each wirelessly connected to the company’s analytic software. This wireless feature can also help researchers capture and analyze growth data as it happens, enabling them to monitor and adjust their experiments in real time.

Until now, researchers faced the constraints of limited off-the-shelf co-culture options, demanding substantial investments of time and resources in developing custom systems for their studies. “Cerillo is dedicated to liberating microbiome researchers from the constraints of conventional laboratory technologies,” says Eric Mayton, CEO of Cerillo. “Our new co-culture system is a game-changer since it is the world’s first scalable, user-friendly, and cost-effective co-culture system.”

Applications

Cerillo’s co-culture system enables researchers to:

  • Mimic natural conditions: Microorganisms in the environment often exist in complex communities, where they interact with each other. Cerillo’s co-culture system allows researchers to mimic these natural conditions and study the interactions between microorganisms.
  • Improve understanding of microbial interactions: Cerillo’s co-culture system can provide insight into how microorganisms interact with each other. For example, one microorganism may produce a compound that benefits another microorganism, or one microorganism may inhibit the growth of another. These interactions can be difficult to study in isolation.
  • Identify novel compounds: Our system can also be used to identify novel compounds that are produced by microorganisms. For example, one microorganism may produce a compound that is only active in the presence of another microorganism.
  • Develop new therapies: Cerillo’s co-culture system can be used to screen for potential therapeutics by testing the ability of a compound to inhibit the growth of a pathogenic microorganism in the presence of a beneficial microorganism.

Features and Benefits

  • multiplexed plate accommodates 18 duets
  • physically accessible wells enable population sampling during and after experiments
  • compatible with other automation systems, giving you the freedom and flexibility to run additional assays on different platforms
  • effective for quick proofs-of-concept, and also preconfigured for higher-throughput work, making it suitable for a wide range of experiment types
  • scalable, enabling high-throughput experiments for faster results and comprehensive data analysis
  • small and robust to harsh conditions of incubators and anaerobic chambers
  • easily access your data without physical contact with your plate reader and manual memory cards

Learn more.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and